Pristimerin Inhibits Breast Cancer Cell Migration by Up-regulating Regulator of G Protein Signaling 4 Expression |
Mu, Xian-Min
(Jiangsu Center of Drug Screening, China Pharmaceutical University)
Shi, Wei (Department of New Drug Screening, Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd,) Sun, Li-Xin (Jiangsu Center of Drug Screening, China Pharmaceutical University) Li, Han (Jiangsu Center of Drug Screening, China Pharmaceutical University) Wang, Yu-Rong (Jiangsu Center of Drug Screening, China Pharmaceutical University) Jiang, Zhen-Zhou (Jiangsu Center of Drug Screening, China Pharmaceutical University) Zhang, Lu-Yong (Jiangsu Center of Drug Screening, China Pharmaceutical University) |
1 | Adams J (2003). The proteasome: structure, function, and role in the cell. Cancer Treat Rev, 29 Suppl 1, 3-9. |
2 | Albig AR SW (2005). Identification and characterization of regulator of G protein signaling 4 (RGS4) as a novel inhibitor of tubulogenesis. Mol Biol Cell, 16, 609-25. |
3 | Bodenstein J, Sunahara RK, Neubig RR (2007). N-terminal residues control proteasomal degradation of RGS2, RGS4, and RGS5 in human embryonic kidney 293 cells. Mol Pharmacol, 71, 1040-50. DOI |
4 | Boire A, Covic L, Agarwal A, et al (2005). PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell, 120, 303-13. DOI ScienceOn |
5 | Byun JY, Kim MJ, Eum DY, et al (2009). Reactive oxygen species-dependent activation of Bax and poly(ADP-ribose) polymerase-1 is required for mitochondrial cell death induced by triterpenoid pristimerin in human cervical cancer cells. Mol Pharmacol, 76, 734-44. DOI |
6 | Chambers AF, Groom AC, MacDonald IC (2002). Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer, 2, 563-72. DOI |
7 | Chen L, Madura K (2005). Increased proteasome activity, ubiquitin-conjugating enzymes, and eEF1A translation factor detected in breast cancer tissue. Cancer Res, 65, 5599-606. DOI |
8 | Costa PM, Ferreira PM, Bolzani Vda S, et al (2008). Antiproliferative activity of pristimerin isolated from Maytenus ilicifolia (Celastraceae) in human HL-60 cells. Toxicol In Vitro, 22, 854-63. DOI |
9 | Dahlmann B (2007). Role of proteasomes in disease. BMC Biochem, 8 Suppl 1, S3. DOI |
10 | Dorsam RT, Gutkind JS (2007). G-protein-coupled receptors and cancer. Nat Rev Cancer, 7, 79-94. DOI ScienceOn |
11 | Glickman MH, Ciechanover A (2002). The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev, 82, 373-428. |
12 | Lappano R, Maggiolini M (2011). G protein-coupled receptors: novel targets for drug discovery in cancer. Nat Rev Drug Discov, 10, 47-60. DOI ScienceOn |
13 | Hobson JP, Rosenfeldt HM, Barak LS, et al (2001). Role of the sphingosine-1-phosphate receptor EDG-1 in PDGF-induced cell motility. Science, 291, 1800-3. DOI |
14 | Huang C, Hepler JR, Gilman AG, et al. (1997). Attenuation of Gi- and Gq-mediated signaling by expression of RGS4 or GAIP in mammalian cells. Proc Natl Acad Sci U S A, 94, 6159-63. DOI |
15 | Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90. DOI |
16 | Lee MJ, Tasaki T, Moroi K, et al (2005). RGS4 and RGS5 are in vivo substrates of the N-end rule pathway. Proc Natl Acad Sci U S A, 102, 15030-5. DOI |
17 | Neves SR, Ram PT, Iyengar R (2002). G protein pathways. Science, 296, 1636-9. DOI ScienceOn |
18 | Ross EM, Wilkie TM (2000). GTPase-activating proteins for heterotrimeric G proteins: regulators of G protein signaling (RGS) and RGS-like proteins. Annu Rev Biochem, 69, 795-827. DOI ScienceOn |
19 | Schlunck G, Damke H, Kiosses WB, et al (2004). Modulation of Rac localization and function by dynamin. Mol Biol Cell, 15, 256-67. |
20 | Schwartz AL, Ciechanover A (2009). Targeting proteins for destruction by the ubiquitin system: implications for human pathobiology. Annu Rev Pharmacol Toxicol, 49, 73-96. DOI |
21 | Tiedemann RE, Schmidt J, Keats JJ, et al (2009). Identification of a potent natural triterpenoid inhibitor of proteosome chymotrypsin-like activity and NF-kappaB with antimyeloma activity in vitro and in vivo. Blood, 113, 4027-37. DOI |
22 | Wu CC, Chan ML, Chen WY, et al (2005). Pristimerin induces caspase-dependent apoptosis in MDA-MB-231 cells via direct effects on mitochondria. Mol Cancer Ther, 4, 1277-85. DOI |
23 | Valentiner U, Haane C, Nehmann N, et al (2009). Effects of bortezomib on human neuroblastoma cells in vitro and in a metastatic xenograft model. Anticancer Res, 29, 1219-25. |
24 | Van Haastert PJ, Devreotes PN (2004). Chemotaxis: signalling the way forward. Nat Rev Mol Cell Biol, 5, 626-34. DOI |
25 | Varshavsky IVDaA (2000). RGS4 is arginylated and degraded by the N-end rule pathway in vitro. J Biol Chem, 275, 22931-41. DOI |
26 | Xie GX PP (2007 ). How regulators of G protein signaling achieve selective regulation. J Mol Biol, 366, 349-65. DOI |
27 | Xie Y, Wolff DW, Wei T, et al (2009). Breast cancer migration and invasion depend on proteasome degradation of regulator of G-protein signaling 4. Cancer Res, 69, 5743-51. DOI |
28 | Yamada H, Abe T, Li SA, et al (2009). Dynasore, a dynamin inhibitor, suppresses lamellipodia formation and cancer cell invasion by destabilizing actin filaments. Biochem Biophys Res Commun, 390, 1142-8. DOI |
29 | Yang H, Landis-Piwowar KR, Lu D, et al (2008). Pristimerin induces apoptosis by targeting the proteasome in prostate cancer cells. J Cell Biochem, 103, 234-44. DOI |
30 | Yau C, Esserman L, Moore DH, et al (2010). A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer. Breast Cancer Res, 12, R85. DOI |
![]() |